TrakCel to expand largest commercial CGT integrated partner network

Published: 4-Mar-2024

The growing ecosystem supports the OCELLOS cellular orchestration platform, allowing users greater choice and more collaborative opportunities in a cost-efficient manner

TrakCel, the leading and proven provider of cellular orchestration systems to the global cell and gene therapy (CGT) industry, announces the coming expansion of its OCELLOS partner ecosystem, which will bring the total number of integrated partners to 20 by the end of 2024.

The growth will mean developers using OCELLOS for cellular orchestration will have even more options for the complex management required to manufacture CGTs.

The OCELLOS network already includes the broadest choice of integrated supply chain partners in the industry, including partners for logistics, hub services, labelling, manufacturing execution systems (MES), enterprise resource planning (ERP) and contract research and manufacturing organisations.

TrakCel supports more than 25 CGTs with its OCELLOS system at every step of clinical development, including many that have progressed through multiple stages to commercialisation.

With the most commercial deployments in the industry, TrakCel's platform continues to lead the way in supporting the advancement of life-saving therapies.

Given its track record of sustainable growth, the company will continue building its integrated network with confidence by more than 40% this year.

OCELLOS users can expect full support from each integrated partner, which has been the case for existing partners such as Lonza, Cencora, QuickStat, Marken, Biocair, Körber and Cardinal Health.

TrakCel ensures each partner has a dedicated technical contact and proactive liaison for product development on hand, alongside training programmes when necessary.

This ensures that OCELLOS remains the data consolidation point at the centre of the manufacturing process.

TrakCel’s broad customer base incentivises partners to maintain optimal operability, and in turn, its large network of partners enhances the ability of OCELLOS to meet the variety of CGT developer needs to support clinical and commercial operations.

Like this story? Subscribe to Manufacturing Chemist magazine for the latest news, updates and expert-written articles from the global pharmaceutical and biopharma sectors. For more information click here.

“For many advanced therapy developers, scaling out from clinical trials and into commercialisation requires more partners. Leveraging our expanded ecosystem allows OCELLOS users to advance without the need for bespoke systems requiring expensive, complex and difficult-to-manage integrations,” says Chris Came, VP Relationship Management, TrakCel.

“Working with OCELLOS means reassurance that as they grow, CGT developers will have the support needed for the vital work of bringing new life-saving medicines to patients.”

You may also like